VT-EBV-N is an autologous EBV-specific cytotoxic T-lymphocyte therapy designed to eliminate residual EBV-infected malignant cells that may persist despite CR. Given the high relapse risk associated with ENKL and the absence of an established post-remission standard of care, VT-EBV-N is being developed as a strategy to prolong remission and prevent disease recurrence.

This randomized, double-blind, placebo-controlled Phase II study enrolled patients with EBV-positive ENKL who had achieved a CR within 6 months before enrollment. Patients were randomized to receive either VT-EBV-N or autologous peripheral blood mononuclear cells (PBMCs) as a control.

Safety Outcomes-

• No deaths occurred in the VT-EBV-N group, whereas 4 deaths (16.0%) were observed in the control group (p = 0.0580).

• VT-EBV-N was generally well tolerated. 

• Grade ≥3 adverse events occurred in 2/21 (9.5%) patients in the VT-EBV-N group and 4/25 (16%) in the control group. 

• No treatment-related deaths were reported.

KOL Insights-

“VT-EBV-N demonstrated a favorable and manageable safety profile as post-remission therapy, with no Grade 3 or greater treatment-related adverse events observed. This study provides robust evidence supporting VT-EBV-N as an effective consolidation strategy for relapse prevention.”– Expert Opinion

“Additional biomarker, translational, and subgroup analyses are needed to better characterize the patients most likely to benefit from VT-EBV-N. Longer follow-up will be essential to confirm the durability of benefit and potential survival impact, while patient-reported outcomes and studies in more diverse populations will further inform its clinical utility and broader applicability.” – Expert Opinion

Conclusion-

Extranodal NK/T-cell lymphoma (ENKL) is a rare and aggressive subtype of non-Hodgkin lymphoma, accounting for approximately 5–10% of peripheral T-cell lymphomas and <1% of all non-Hodgkin lymphoma cases globally. Despite achieving complete remission with intensive therapy, a substantial proportion of patients experience disease relapse, and no established post-remission standard of care currently exists.

In this randomized Phase II trial, VT-EBV-N significantly improved 2-year DFS with a favorable safety profile compared with control therapy. These findings provide important evidence supporting EBV-targeted cellular immunotherapy as a novel post-remission strategy and highlight the potential of VT-EBV-N to address a critical unmet need in EBV-positive ENKL. If validated in larger studies, VT-EBV-N could emerge as a new standard post-remission approach for this rare but clinically challenging lymphoma.